Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.52
0.0000
Volume:10
Turnover:365.61
Market Cap:19.17M
PE:- -
High:36.52
Open:36.52
Low:36.52
Close:36.52
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.03
T/O Rate:0.00%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Huihe Medical's STAR Market IPO Application Terminated; Company Focuses on Innovative Medical Devices in Panvascular Intervention

Stock News
·
Sep 24

UnitedHealth Adds Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

Reuters
·
Sep 24

UnitedHealth Group Announces Addition to Leadership Team

THOMSON REUTERS
·
Sep 24

UnitedHealth - Appoints Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

THOMSON REUTERS
·
Sep 24

Lifetech Scientific's SureCham Aortic Arch Single-Branch Stent Graft System Enters Special Review Pathway for Innovative Medical Devices

Stock News
·
Sep 24

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

GlobeNewswire
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166

TIPRANKS
·
Sep 24

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

GlobeNewswire
·
Sep 24

Bioperfectus Secures Two Medical Device Registration Certificates

Stock News
·
Sep 24

Maccura Biotechnology Secures Three Medical Device Registration Certificates

Stock News
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24